by Elena Iemma | Nov 30, 2021 | News
PROVIDENCE, RI, November 30, 2021 /PRNewswire/ — Today EpiVax, Inc. (“EpiVax”) confirmed that the company’s EPV-CoV-19 vaccine epitope sequences are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc....
by Elena Iemma | May 17, 2021 | News
PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies...
by Adam | Dec 31, 2020 | News
PROVIDENCE, R.I., Dec. 31, 2020 /PRNewswire/ — EpiVax (“EpiVax”) and EpiVax Therapeutics (“EVT”) today provide an update on the advancement of their peptide-based COVID-19 vaccine, EPV-CoV-19. EPV-CoV-19, a T cell epitope-based vaccine...
by Annie De Groot | Sep 21, 2020 | Events, Webinars
Thank you for your continued interest in the status of our EpiVax’s EPV-CoV-19 Vaccine Program. This event has passed! But do not fear, there is a recording of the session available for access. Kindly fill out the information form linked below and an email...
by Adam | Jul 24, 2020 | News
Are we “Checking the Box” or Making Vaccines that work? We need a COVID-19 vaccine! From China to the US to Europe and even Africa, scientists are working tirelessly, if not at “warp speed”, to develop and test more than one COVID-19...
